Drug Trial Radar · NCT03563170
QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine
Last checked: Nov 20, 2026Latest source record: Mar 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
May 25, 2018
Primary completion
Aug 23, 2019
Study completion Aug 23, 2019
Sponsor
- Lead sponsor
- ImmunityBio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 20, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with advanced, unresectable, and untransplantable HCC.
Conditions
- Hepatocellular Carcinoma Non-resectable
- Hepatocellular Carcinoma Recurrent
Interventions
ETBX-011Biological
Ad5 \[E1-, E2b-\]-CEA
GI-4000Biological
Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant RAS proteins
haNK for infusionBiological
NK-92 \[CD16.158V, ER IL-2\]
avelumabBiological
Recombinant human anti-PD-L1 IgG1 monoclonal antibody
CapecitabineDrug
5'-deoxy-5-fluoro-N-\[(pentyloxy) carbonyl\]-cytidine
CyclophosphamideDrug
anhydrous
5-FluorouracilDrug
5-FU; Fluorouracil
LeucovorinDrug
Leucovorin calcium salt
nab-PaclitaxelDrug
ABRAXANE® \[paclitaxel protein-bound particles for injectable suspension\] \[albumin-bound\]
SorafenibDrug
NEXAVAR® tablets, for oral use
SBRTProcedure
Stereotactic Body Radiation Therapy
Aldoxorubicin hydrochlorideBiological
HCl
ETBX-051Biological
Ad5 \[E1-, E2b-\]-Brachyury vaccine
ETBX-061Biological
Ad5 \[E1-, E2b-\]-mucin 1 \[MUC1\] vaccine
GI-6207Biological
CEA yeast vaccine
GI-6301Biological
Brachyury yeast vaccine
CetuximabDrug
ERBITUX® injection, for IV infusion)
N-803Biological
Recombinant human super agonist IL-15 complex \[also known as IL-15N72D:IL- 15RαSu/IgG1 Fc complex\]
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent AEs and SAEs, graded using the NCI CTCAE Version 4.03Time frame: 2 years
- Evaluate the overall safety profile in subjects with advanced, unresectable, untransplantable HCC who have progressed or experienced unacceptable toxicity on prior sorafenib treatment. Measured / reported based on the tumor size imaging per RECIST 1.1.Time frame: 2 years
- Progression Free Survival from baseline to progression, per RECIST 1.1Time frame: 2 years
- Overall Response Rate, as determined by the percentage of patients achieving Partial or Complete Response per RECIST 1.1Time frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Chan Soon-Shiong Institute for Medicine
El Segundo, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.